The anthracyclines are effective and widely used antineoplastic agents. They are used to treat many types of malignancy including acute lymphoblastic leukaemia.' Their introduction has considerably improved survival, especially in childhood cancers.
Signs of cardiac toxicity may develop during, soon after or many years after a course of treatment. Early toxicity is dependent principally on the cumulative anthracycline dose. Typically the patient presents with left ventricular or congestive heart failure and with clinical features of congestive cardiomyopathy. Less often an arrhythmia is the first manifestation of toxicity. The major differential diagnoses are malignant pericarditis, cardiac injury from concomitant radiotherapy, and coincidental heart muscle or coronary artery disease.
The two most widely used and studied anthracyclines are daunorubicin and its C-14 derivative, doxorubicin (adriamycin). They are glycoside antibiotics that owe their antineoplastic action to a complex effect that results in inhibition of nucleic acid synthesis by binding to both strands of the DNA helix, preventing the normal function of RNA and DNA polymerases. Effects on ventricular function Dose-dependent myocardial toxicity is characterised by impairment of left ventricular diastolic function which is followed by reduced systolic function7-9 with progressive left ventricular free wall thinning and dilatation.10 Dysfunction confined to the right ventricle has also been described.1' 12 An upper limit to the cumulative dose of 450-550 mg/M2 was recommended."134
Non-dose dependent electrocardiographic abnormalities including non-specific ST and T wave changes, low QRS voltage, and ventricular arrhythmias were described in a review of patients with evidence of early cardiotoxicity. 15 Steinberg et al observed arrhythmias in 3% of patients during the first hour of doxorubicin administration, increasing to 24% of subjects within the first 24 hours. The most common abnormality was an increase in the frequency of ventricular extrasystoles but a few patients developed non-sustained ventricular tachycardia. The appearance of arrhythmias was not associated with an adverse outcome in this group of patients '6 but sudden death has been reported by others. '7 Early congestive cardiac failure developed in about 30% of patients receiving more than 550 mg/M2 doxorubicin but in only 0 01-0 27% of patients receiving less than 550 mg/m2.1'20 Smaller doses of anthracycline can lead to a reduction in myocardial function that is demonstrable only on exercise.2122 Cardiotoxicity can be enhanced when anthracyclines are used in combination with other agents such as cyclophosphamide, bleomycin, cisplatin, methotrexate, and mitomycin C2324 as well as with thoracic irradiation. Cumulative anthracycline doses below the "safe upper limit" of 450-550 mg/M2 can be fatal in these circumstances.
Heart failure late after anthracycline therapy is increasingly recognised. [25] [26] [27] [28] [29] In a prospective study of 201 children treated with anthracyclines, Steinherz and colleagues found that no patient assessed [4] [5] [6] years after treatment had a fractional shortening of less than 20%, whereas by 10 an earlier indication of cardiotoxicity. Ideally methods of identifying patients at risk of cardiotoxicity, or of identifying cardiotoxicity before it causes irreversible depression of myocardial function need to be developed.
Monoclonal antimyosin antibody imaging has been proposed for the early diagnosis of anthracycline cardiotoxicity5253 because antibody uptake seems to predate other markers of myocardial damage. Evidence from 123I. Methoxy-isobutyl isonitrile (MIBI) scanning suggests that doxorubicin-related cardiotoxicity involves myocardial adrenergic derangement,54 pointing to the possibility that the study of cardiac autonomic function could be helpful for patient monitoring. One study showed a reduction in respiratory sinus arrhythmia that preceded the onset of clinical congestive cardiac failure by several months55; however, another study that identified abnormalities in cardiovascular responses to hand grip and standing found no correlation with ventricular function. 56 The 
